特应性皮炎；Janus激酶抑制剂；度普利尤单抗；乌帕替尼；托法替布," /> 特应性皮炎；Janus激酶抑制剂；度普利尤单抗；乌帕替尼；托法替布,"/> atopic dermatitis,Janus kinase (JAK) inhibitors,dupilumab,upadacitinib,tofacitinib,"/> <span style="font-size:12px;">Two children with refractory atopic dermatitis successfully treated with Janus kinase inhibitors</span>

China Journal of Leprosy and Skin Diseases ›› 2024, Vol. 40 ›› Issue (3): 190-192.doi: 10.12144/zgmfskin202403190

• Clinical Researches • Previous Articles     Next Articles

Two children with refractory atopic dermatitis successfully treated with Janus kinase inhibitors

HAN Jinghong1,2, LIU Hong1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China;2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2024-03-15 Published:2024-02-27

PDF (PC)

29

Like

Abstract: Atopic dermatitis (AD) is a common chronic inflammatory skin disease that significantly impairs the quality of life. Recently, novel biologics and small-molecule oral drugs have gained approval for the treatment of AD. Janus kinase (JAK) inhibitors play a therapeutic role in atopic dermatitis by inhibiting various Th2 cell-mediated inflammation, impaired epidermal barrier function, and pruritus signaling pathways. This article reports two cases of pediatric patients with refractory atopic dermatitis successfully treated with JAK inhibitors.

Key words: atopic dermatitis')">atopic dermatitis, Janus kinase (JAK) inhibitors, dupilumab, upadacitinib, tofacitinib